https://radboudtranslationalmedicine.nl/en/news/linkedin-post-isologic-goes-electric1.0weekly2025-03-14T09:39:56+01:00https://radboudtranslationalmedicine.nl/en/about-us/stijn-bekker1.0weekly2025-03-06T09:41:56+01:00https://radboudtranslationalmedicine.nl/en/products/radelumin-18f-psma-10071.0weekly2025-03-18T12:56:21+01:00https://radboudtranslationalmedicine.nl/en/products/neuraceq-18f-florbetaben1.0weekly2025-03-18T12:52:50+01:00https://radboudtranslationalmedicine.nl/en/about-us/chinouk-klaassen-heijmans1.0weekly2025-02-26T09:06:33+01:00https://radboudtranslationalmedicine.nl/en/about-us/chang-guo1.0weekly2024-05-27T09:58:15+02:00https://radboudtranslationalmedicine.nl/en/news/rtm-added-as-distributor-neuraceq1.0weekly2024-05-24T14:22:50+02:00https://radboudtranslationalmedicine.nl/en/news/first-patient-dosed-with-tlx250-cdx-in-italy-for-ccrcc1.0weekly2024-03-28T07:58:03+01:00https://radboudtranslationalmedicine.nl/en/news/linkedin-post-esrr20241.0weekly2024-01-29T08:25:42+01:00https://radboudtranslationalmedicine.nl/en/products/radio-flu-18f-naf-21.0weekly2026-01-05T11:07:52+01:00https://radboudtranslationalmedicine.nl/en/news/abx-has-received-marketing-authorisation-for-the-radiotracer-radelumin-in-germany1.0weekly2023-11-15T14:34:29+01:00https://radboudtranslationalmedicine.nl/en/news/first-patient-dosed-in-phase-ii-study-of-tlx250-cdx-in-triple-negative-breast-cancer-31.0weekly2023-12-04T17:04:03+01:00https://radboudtranslationalmedicine.nl/en/about-us/ginny-van-der-sluys1.0weekly2023-04-03T09:26:08+02:00https://radboudtranslationalmedicine.nl/en/about-us/kristell-chatalic1.0weekly2023-04-13T08:35:59+02:00https://radboudtranslationalmedicine.nl/en/about-us/marielle-kersten1.0weekly2024-06-03T08:00:26+02:00https://radboudtranslationalmedicine.nl/en/news/huntingtons-disease-a-review-of-the-known-pet-imaging-biomarkers-and-targeting-radiotracers1.0weekly2023-02-16T15:22:19+01:00https://radboudtranslationalmedicine.nl/en/about-us/anne-van-de-beek1.0weekly2024-10-02T09:13:00+02:00https://radboudtranslationalmedicine.nl/en/news/cooperation-rtm-alliance-medical1.0weekly2023-02-16T15:22:19+01:00https://radboudtranslationalmedicine.nl/en/news/rtm-receives-marketing-authorisation-for-fludeoxyglucose-18f1.0weekly2023-02-16T15:22:19+01:00https://radboudtranslationalmedicine.nl/en/news/1st-production-quiremspheres1.0weekly2023-02-16T15:22:18+01:00https://radboudtranslationalmedicine.nl/en/news/production-of-novel-diagnostic-radionuclides-in-small-medical-cyclotrons1.0weekly2023-02-16T15:22:18+01:00https://radboudtranslationalmedicine.nl/en/cookie-statement1.0weekly2023-02-16T15:22:18+01:00https://radboudtranslationalmedicine.nl/en/news/first-liver-cancer-patient-treated-with-microspheres-irradiated-in-tu-delft1.0weekly2023-02-16T15:22:18+01:00https://radboudtranslationalmedicine.nl/en/collaborations1.0weekly2023-02-16T15:22:17+01:00https://radboudtranslationalmedicine.nl/en/news/18f-fdopa-now-available1.0weekly2023-02-16T15:22:19+01:00https://radboudtranslationalmedicine.nl/en/jobs1.0weekly2024-09-16T08:48:37+02:00https://radboudtranslationalmedicine.nl/en/news/gmp-certificate-received1.0weekly2023-02-16T15:26:09+01:00https://radboudtranslationalmedicine.nl/en/news/gmp-certificate-received-21.0weekly2023-02-16T15:22:19+01:00https://radboudtranslationalmedicine.nl/en/news/upcoming-event1.0weekly2023-02-16T15:22:19+01:00https://radboudtranslationalmedicine.nl/en/disclaimer1.0weekly2023-02-16T15:22:09+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/is-such-a-major-investment-justifiable-in-this-time-of-cost-containment-and-budget-constraints1.0weekly2023-02-16T15:22:04+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/whats-in-it-for-the-patient1.0weekly2023-02-16T15:22:05+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/why-the-name-translational-medicine1.0weekly2023-02-16T15:22:01+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/does-the-cyclotron-yield-any-radioactive-waste1.0weekly2023-02-16T15:22:04+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/how-much-radioactive-material-will-be-produced-by-the-cyclotron1.0weekly2023-02-16T15:22:02+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/what-are-the-costs-associated-with-the-construction-of-this-facility1.0weekly2023-02-16T15:22:04+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/what-are-the-risks-of-a-cyclotron-facility1.0weekly2023-02-16T15:22:02+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/why-has-this-cyclotron-facility-been-constructed1.0weekly2023-02-16T15:22:02+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/are-the-radioactive-materials-produced-dangerous1.0weekly2023-02-16T15:22:03+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/what-is-a-pet-scan1.0weekly2023-02-16T15:22:03+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/how-much-radiation-is-a-patient-exposed-to-during-a-pet-scan1.0weekly2023-02-16T15:22:03+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/is-the-radioactive-material-administered-for-a-pet-scan-harmful1.0weekly2023-02-16T15:22:03+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/can-there-be-a-melt-down-in-a-cyclotron-with-all-negative-consequences1.0weekly2023-02-16T15:22:04+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions/what-is-a-cyclotron1.0weekly2023-02-16T15:22:01+01:00https://radboudtranslationalmedicine.nl/en/products/11c-tracers1.0weekly2023-02-16T15:21:51+01:00https://radboudtranslationalmedicine.nl/en/research1.0weekly2023-02-16T15:22:01+01:00https://radboudtranslationalmedicine.nl/en/frequently-asked-questions1.0weekly2023-02-16T15:22:05+01:00https://radboudtranslationalmedicine.nl/en/contact1.0weekly2024-11-13T08:44:37+01:00https://radboudtranslationalmedicine.nl/en/general-conditions1.0weekly2023-12-18T09:31:02+01:00https://radboudtranslationalmedicine.nl/en/about-us1.0weekly2023-08-04T11:54:42+02:00https://radboudtranslationalmedicine.nl/en/about-us/lars-perk1.0weekly2023-04-13T08:32:28+02:00https://radboudtranslationalmedicine.nl/en/about-us/vera-bloemers1.0weekly2023-03-21T09:45:33+01:00https://radboudtranslationalmedicine.nl/en/about-us/mateusz-synowiecki1.0weekly2023-03-21T09:42:54+01:00https://radboudtranslationalmedicine.nl/en/products1.0weekly2023-02-16T15:21:52+01:00https://radboudtranslationalmedicine.nl/en1.0weekly2023-02-16T15:21:50+01:00https://radboudtranslationalmedicine.nl/en/news1.0weekly2023-02-16T15:22:20+01:00